- Trials with a EudraCT protocol (5)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
5 result(s) found for: Linoleic acid.
Displaying page 1 of 1.
| EudraCT Number: 2005-003197-17 | Sponsor Protocol Number: 3239E | Start Date*: 2006-09-13 |
| Sponsor Name:Cardiff and Vale NHS Trust | ||
| Full Title: The Metabolic,Vascular and Inflammatory effects of Conjugated Linoleic acid in patients with the Metabolic Syndrome. | ||
| Medical condition: METABOLIC SYNDROME | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: GB (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-004814-33 | Sponsor Protocol Number: MOFA | Start Date*: 2006-03-23 |
| Sponsor Name:Gesellschaft für Wissens- und Technologietransfer | ||
| Full Title: Metabolic optimized fast track concept in general surgery | ||
| Medical condition: Carcinoma of the colon or the liver scheduled for surgical resection | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2010-021018-49 | Sponsor Protocol Number: FOILED | Start Date*: 2012-05-25 | ||||||||||||||||
| Sponsor Name:GWT-TUD GmbH | ||||||||||||||||||
| Full Title: Fish OIL optimal dosE Determination Study | ||||||||||||||||||
| Medical condition: Mechanically ventilated adult patients (>18 years old) admitted to ICU with clinical evidence of sepsis, sepsis associated organ dysfunction, and high expression of inflammatory cytokines. | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2019-002278-30 | Sponsor Protocol Number: APH-19 | Start Date*: 2020-08-12 | |||||||||||
| Sponsor Name:Amryt Pharmaceuticals DAC | |||||||||||||
| Full Title: Phase III, single-arm, open-label, international, multi-centre study to evaluate the efficacy and safety of lomitapide in paediatric patients with Homozygous Familial Hypercholesterolaemia (HoFH) o... | |||||||||||||
| Medical condition: Homozygous familial hypercholesterolaemia (HoFH). A rare and life-threatening inherited disorder of lipid metabolism with an estimated prevalence of 1 per 160,000 to 300,000 in the European populat... | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-004645-36 | Sponsor Protocol Number: TMP-2501-2019-2 | Start Date*: 2021-05-31 | |||||||||||
| Sponsor Name:Fraunhofer Gesellschaft for its Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP) | |||||||||||||
| Full Title: Impact of different silymarin dosages to decrease drug-induced elevated liver enzymes compared to placebo in a prospective controlled dose finding Phase IIb trial (SILVER) | |||||||||||||
| Medical condition: Drug-induced elevated liver enzymes | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.